hypermethylation in patients with kidney cancer: results of a prospective
study. Anticancer Res. 2013; 33:4651–4656.
9. Bergerot PG, Hahn AW, Bergerot CD, et al. The role of circulating tumor
DNA in renal cell carcinoma. Current Treatment Options in Oncology. 2018;
19(2): https://doi.org/10.1007/s11864-018-0530-4.
10. Govindan R. Cancer. Attack of the clones. Science. 2014;346:169–
70.
11. Gremel G, Lee RJ, Girotti MR, Mandal AK, Valpione S, Garner G, et
al. Distinct subclonal tumour responses to therapy revealed by circulating
cellfree DNA. Ann Oncol. 2016;27:1959–65.
12. Murtaza M, Dawson S-J, Pogrebniak K, Rueda OM, Provenzano E,
Grant J, et al. Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun.
2015;6:8760.
13. Sacher AG, Paweletz C, Dahlberg SE,Alden RS,O’Connell A, Feeney
N, et al. Prospective validation of rapid plasma genotyping for the detection
of EGFR and KRAS mutations in advanced lung cancer. JAMA
Oncol. 2016;2:1014–22.
14. Vall_ee A, Audigier-Valette C, Herbreteau G, Merrien J, Tessonnier
L,Theoleyre S, et al. Rapid clearance of circulating tumor DNA during
treatment with AZD9291 of a lung cancer patient presenting the resistance
EGFR T790M mutation. Lung Cancer. 2016;91:73–4.
15. Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, DelGrammastro
M, et al. Early prediction of response to tyrosine kinase inhibitors
by quantification of EGFR mutations in plasma of NSCLC
patients: J Thorac Oncol. 2015;10:1437–43.
16. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin
T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung
cancer evolution. Nature. 2017;545:446–51.
17. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins
TBK, Veeriah S, et al. Tracking the evolution of non-small-cell lung cancer.
N Engl J Med. 2017;376:2109–21.
18. Raja R, Kuziora M, Brohawn PZ, et al. Early reduction in ctDNA predicts
survival in patients with lung and bladder cancer treated with
durvalumab. Clin Can Res. 2018;24:6212-6222.
19. Zill OA, Banks KC, Fairclough SR, et al. The landscape of actionable
genomic alterations in cell-free circulating tumor DNA from 21,807 advanced
cancer patients. Clin Can Res. 2018;24:3528-3538.
20.Wan , Zhu L, Jiang Z, et al. Monitoring of plasma cell-free DNA in
predicting postoperative recurrence of clear cell renal cell carcinoma.
Urol Int. 2013;91:273-278.
21. Hahn AW, Gill DM, Maughan B, et al. Correlation of genomic alterations
assessed by next-generation sequencing (NGS) of tumor tissue
DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma
(mRCC): potential clinical implications. Oncotarget. 2017;8:
33614-33620.
22. Khagi Y, Goodman AM, Daniels GA, et al. Hypermutated circulating
tumor DNA: correlation with response to checkpoint inhibitor-based
immunotherapy. Clin Can Res. 2017;23:5729-5736.
23. Dizman N, Bergerot P, Bergerot C, et al. Exceptional response to
nivolumab rechallenge in metastatic renal cell carcinoma with parallel
changes in genomic profile. Eur Urol. 2018;73:306-310.
24. Maia MC., Bergerot PG,. Dizman N., Hsu J., Jones J., Lanman R.,
Banks KC., Pal SK. Association of Circulating tumor DNA (ctDNA) Detection
in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden.
Kidney Cancer. 2017 ; 1(1):65-70
25. Pal SK, Sonpavde G, Agarwal N, et al. Evolution of circulating tumor
DNA profile from first-line to subsequent therapy in metastatic renal
cell carcinoma. Eur Urol. 2017;72:557-564.
266. Ikeda S, Schwaderle M, Mohindra M, et al. Met alterations in
blood-derived circulating tumor DNA correlate with bone metastases
and poor prognosis. J Hematol Oncol. 2018;11:76. doi:10.1186/s13045-
018-0610-8
27. Kotecha R, Gedvilaite E, Murray S, et al. Comparative genpomic
profiling from tumor tissue and circulating tumor DNA (ctDNA) in 111
patients (Pts) with metastatic clear cell renal cell carcinoma. J Clin
Oncol. 2019; 37:15_suppl, 4565-4565.
28. Correa A, Conolly DC, Balcioglu M, et al. Presence of circulating
tumor DNA in surgically resected renal cell carcinoma is associated
with advanced disease and poor patient prognosis. Ann Oncol.
2019;30:Suppl 5;110P. https://doi.org/10.1093/annonc/mdz239.021KCJ
• Highlights and Analyses from the
2020 Scientific Sessions of the
American Society of Clincal Oncology
• Targeted Therapy Following
Immuno-oncology Approaches in
RCCa: Challenges and Guidelines
/s11864-018-0530-4
/mdz239.021KCJ